The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine

Kevin D. Pavelko, Michael P. Bell, Lavakumar Karyampudi, Michael J. Hansen, Kathleen S. Allen, Keith L Knutson, Larry R Pease

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Picornaviruses have been developed as potential therapies for gene delivery and vaccination. One drawback to their use is the potential for recombination and viral persistence. Therefore, the engineering strategies used must take into account the possibility for virus escape. We have developed Theiler's murine encephalomyelitis virus (TMEV) as a potential vaccine vector for use in immunotherapy. This study shows that insertion of a vaccine epitope at a unique site within the TMEV leader protein can dramatically increase the type I interferon (IFN) response to infection and promote rapid viral clearance. This live virus vaccine maintains its ability to drive antigen-specific CD8 + T-cell responses to a model antigen as well as to the weakly immunogenic tumor antigen Her2/neu. Furthermore, the epitope integration site does not affect the efficacy of this vaccine as cancer immunotherapy for treating models of melanoma and breast cancer as demonstrated by delayed tumor outgrowth and increased survival in animals implanted with these tumors. These findings show that an attenuated virus retaining limited ability to replicate nonetheless can effectively mobilize CD8 + cellular immunity and will be important for the design of picornavirus vectors used as immunotherapy in clinical settings.

Original languageEnglish (US)
Pages (from-to)1087-1095
Number of pages9
JournalMolecular Therapy
Volume21
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Cancer Vaccines
Theilovirus
Immunotherapy
Picornaviridae
Epitopes
Vaccines
Viruses
Antigens
CD8 Antigens
Interferon Type I
Neoplasm Antigens
Cellular Immunity
Genetic Therapy
Genetic Recombination
Melanoma
Neoplasms
Vaccination
Breast Neoplasms
T-Lymphocytes
Infection

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. / Pavelko, Kevin D.; Bell, Michael P.; Karyampudi, Lavakumar; Hansen, Michael J.; Allen, Kathleen S.; Knutson, Keith L; Pease, Larry R.

In: Molecular Therapy, Vol. 21, No. 5, 05.2013, p. 1087-1095.

Research output: Contribution to journalArticle

Pavelko, Kevin D. ; Bell, Michael P. ; Karyampudi, Lavakumar ; Hansen, Michael J. ; Allen, Kathleen S. ; Knutson, Keith L ; Pease, Larry R. / The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. In: Molecular Therapy. 2013 ; Vol. 21, No. 5. pp. 1087-1095.
@article{69316b172eef4244b5ac640f514e69f9,
title = "The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine",
abstract = "Picornaviruses have been developed as potential therapies for gene delivery and vaccination. One drawback to their use is the potential for recombination and viral persistence. Therefore, the engineering strategies used must take into account the possibility for virus escape. We have developed Theiler's murine encephalomyelitis virus (TMEV) as a potential vaccine vector for use in immunotherapy. This study shows that insertion of a vaccine epitope at a unique site within the TMEV leader protein can dramatically increase the type I interferon (IFN) response to infection and promote rapid viral clearance. This live virus vaccine maintains its ability to drive antigen-specific CD8 + T-cell responses to a model antigen as well as to the weakly immunogenic tumor antigen Her2/neu. Furthermore, the epitope integration site does not affect the efficacy of this vaccine as cancer immunotherapy for treating models of melanoma and breast cancer as demonstrated by delayed tumor outgrowth and increased survival in animals implanted with these tumors. These findings show that an attenuated virus retaining limited ability to replicate nonetheless can effectively mobilize CD8 + cellular immunity and will be important for the design of picornavirus vectors used as immunotherapy in clinical settings.",
author = "Pavelko, {Kevin D.} and Bell, {Michael P.} and Lavakumar Karyampudi and Hansen, {Michael J.} and Allen, {Kathleen S.} and Knutson, {Keith L} and Pease, {Larry R}",
year = "2013",
month = "5",
doi = "10.1038/mt.2013.52",
language = "English (US)",
volume = "21",
pages = "1087--1095",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine

AU - Pavelko, Kevin D.

AU - Bell, Michael P.

AU - Karyampudi, Lavakumar

AU - Hansen, Michael J.

AU - Allen, Kathleen S.

AU - Knutson, Keith L

AU - Pease, Larry R

PY - 2013/5

Y1 - 2013/5

N2 - Picornaviruses have been developed as potential therapies for gene delivery and vaccination. One drawback to their use is the potential for recombination and viral persistence. Therefore, the engineering strategies used must take into account the possibility for virus escape. We have developed Theiler's murine encephalomyelitis virus (TMEV) as a potential vaccine vector for use in immunotherapy. This study shows that insertion of a vaccine epitope at a unique site within the TMEV leader protein can dramatically increase the type I interferon (IFN) response to infection and promote rapid viral clearance. This live virus vaccine maintains its ability to drive antigen-specific CD8 + T-cell responses to a model antigen as well as to the weakly immunogenic tumor antigen Her2/neu. Furthermore, the epitope integration site does not affect the efficacy of this vaccine as cancer immunotherapy for treating models of melanoma and breast cancer as demonstrated by delayed tumor outgrowth and increased survival in animals implanted with these tumors. These findings show that an attenuated virus retaining limited ability to replicate nonetheless can effectively mobilize CD8 + cellular immunity and will be important for the design of picornavirus vectors used as immunotherapy in clinical settings.

AB - Picornaviruses have been developed as potential therapies for gene delivery and vaccination. One drawback to their use is the potential for recombination and viral persistence. Therefore, the engineering strategies used must take into account the possibility for virus escape. We have developed Theiler's murine encephalomyelitis virus (TMEV) as a potential vaccine vector for use in immunotherapy. This study shows that insertion of a vaccine epitope at a unique site within the TMEV leader protein can dramatically increase the type I interferon (IFN) response to infection and promote rapid viral clearance. This live virus vaccine maintains its ability to drive antigen-specific CD8 + T-cell responses to a model antigen as well as to the weakly immunogenic tumor antigen Her2/neu. Furthermore, the epitope integration site does not affect the efficacy of this vaccine as cancer immunotherapy for treating models of melanoma and breast cancer as demonstrated by delayed tumor outgrowth and increased survival in animals implanted with these tumors. These findings show that an attenuated virus retaining limited ability to replicate nonetheless can effectively mobilize CD8 + cellular immunity and will be important for the design of picornavirus vectors used as immunotherapy in clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=84877023084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877023084&partnerID=8YFLogxK

U2 - 10.1038/mt.2013.52

DO - 10.1038/mt.2013.52

M3 - Article

VL - 21

SP - 1087

EP - 1095

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -